Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

NASH has become a major therapeutic focus for pharma firms in South Korea, where companies are speeding up development and expanding their pipelines after Yuhan’s sizable global license deals last year.

Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.

Conscious Beauty, launching at Ulta in the fall, is built around five pillars for product certification – clean ingredients, cruelty free, vegan, sustainable packaging and positive impact. Clean ingredients means no parabens, phthalates or listed ingredients in 25 other categories, the retailer says.